# BioSpēctrùúm 

## Suven Life Sciences secures product patents

04 July 2018 | News

The granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents for neurodegenerative disorders.


Suven Life Sciences secures four product patents from India, Singapore, South Korea and Israel.
Suven Life Sciences has secured four product patents from India, Singapore, South Korea and Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2031, 2034, 2034 and 2036 respectively.

The granted claims of the patents include the class of selective $5-\mathrm{HT} 4$ compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.

